Viewing Study NCT02049957


Ignite Creation Date: 2025-12-24 @ 6:39 PM
Ignite Modification Date: 2026-02-07 @ 3:01 PM
Study NCT ID: NCT02049957
Status: COMPLETED
Last Update Posted: 2023-02-08
First Post: 2013-12-12
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Sponsor: Calithera Biosciences, Inc
Organization:

Organization Data

Organization:
Class: INDUSTRY
Study ID: C31001
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators